![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Suh John H
Publisher: Informa Healthcare
ISSN: 1354-3784
Source: Expert Opinion on Investigational Drugs, Vol.13, Iss.5, 2004-05, pp. : 543-550
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
By Antila Saila Jarvinen Asko Honkanen Timo Lehtonen Lasse
European Journal of Clinical Pharmacology, Vol. 56, Iss. 9-10, 2000-12 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
The heads up on efaproxiral + brain radiotherapy
Inpharma, Vol. 1, Iss. 1519, 2006-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Expert Opinion on Investigational Drugs, Vol. 9, Iss. 6, 2000-06 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Repaglinide plus an insulin-sensitiser: better glycaemic control
Inpharma, Vol. 1, Iss. 1296, 2001-01 ,pp. :